Press Release Forum [pressreleaseforum.com] Forum Index

Press Release Forum [pressreleaseforum.com]
Free Press Release Distribution

A site of EPR Network

 FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups   RegisterRegister 
 ProfileProfile   Log in to check your private messagesLog in to check your private messages   Log inLog in 

Real Time Press Release Distribution is here. Try it out, it's free!

 

AnaSpec Introduces New MMP Recombinant Proteins

 
Post new topic   Reply to topic    Press Release Forum [pressreleaseforum.com] Forum Index -> Biotech Press Releases
View previous topic :: View next topic  
Author Message
anaspec



Joined: 15 Aug 2006
Posts: 238
Location: 34801 Campus Drive, Fremont, CA 94555

PostPosted: Fri Apr 23, 2010 12:22 pm    Post subject: AnaSpec Introduces New MMP Recombinant Proteins Reply with quote

Fremont, CA – April 23, 2010

AnaSpec has announced the release of three new MMP recombinant proteins, MMP-1, MMP-9 and MMP-12. These proteins, derived from the catalytic domain of the proteins, are supplied as activated proteins (activation by APMA is not necessary). They can be used as positive controls for the SensoLyte® 520 and 490 assays, for western blot, immunoprecipitation, ELISA or zymography.

Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated zinc endopeptidases capable of digesting extracellular matrix components.1-2 MMP-1 (collagenase-1) is involved in tumor development, metastasis and rheumatoid arthritis.3-5 MMP-1 is proposed as a therapeutic target for these diseases. It digests a broad range of substrates, including α-1 antitrypsin, myelin basic protein, collagen I, II, III, VII, VIII, casein, gelatin, and others. 3-5 MMP-9 (92-kDa gelatinase, collagenase-IV) is involved in a number of diseases such as cancer, angiogenesis, alopecia, and metastasis. 6-7 MMP-9 is secreted as zymogen with prodomain, gelatin-binding domain consisting of three contiguous fibronectin type II units, catalytic domain, proline-rich linker region, and C-terminal hemopexin-like domain. It can degrade a variety of substrates, including gelatin, collagens type IV, V, XIV, a2-macroglobulin, elastin, vitronectin, and proteoglycans.1,2,6,7 MMP-12 (macrophage elastase) is involved in smoke-induced emphysema, tumor and other diseases. 8-9 MMP-12 is secreted as a 54-kDa zymogen and becomes the mature 45-kDa active form after proteolytic cleavage. MMP-12 has a broad range of substrates, including α-1 proteinase inhibitor, α-2 antiplasmin, plasminogen activator inhibitor-2, collagen IV, laminin, fibronectin, elastin, but not interstitial collagens.8-9


References:
1. Woessner, J. et al. J. Biol. Chem. 263, 16918 (1988).
2. Woessner, J. FASEB J. 5, 2145 (1991).
3. Goldberg G. I. et al. Ann. N.Y. Acad. Sci. 580, 375 (1990).
4. Stetler-Stevenson, WG. et al. Annu. Rev. Cell Biol. 9, 541(1993).
5. Gravallese, EM. et al. Arthritis Rheum. 34, 1076 (1991).
6. Wilhelm, SM. et al. J. Biol.Chem. 264, 17213 (1989).
7. Fosang, AJ. et al., Biochem.J. 295, 273 (1993).
8. Hautamaki, D. et al. Science 277, 2002 (1997).
9. Dong, Z. et al. Cell 88, 801 (1997).


About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.

For more information visit www.anaspec.com

About Eurogentec

Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.

Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.

For more information visit www.eurogentec.com

###
_________________
Ping Yang
Marketing Speialist
34801 Campus Drive
Fremont, CA 94555
1-800-452-5530 (Toll free)
1-510-791-9560 (Tel)
1-510-791-9572 (Fax)
ping@anaspec.com
www.anaspec.com
Back to top
View user's profile Send private message Send e-mail Visit poster's website
Display posts from previous:   
Post new topic   Reply to topic    Press Release Forum [pressreleaseforum.com] Forum Index -> Biotech Press Releases All times are GMT - 4 Hours
Page 1 of 1

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum

Submit Press Release (Free)Submit Press Release